Man given a year to live now cancer-free after immunotherapy trial
Further studies under way as ‘remarkable’ results offer new hope in treating biliary tract cancerA man given a year to live after being diagnosed with an aggressive form of cancer is now disease-free thanks to a UK trial of a personalised drug regime.Robert Glynn, 51, a welder from Worsley in Greater Manchester, said he “wouldn’t be here” if it were not for the remarkable results of the immunotherapy trial run by the Christie NHS foundation trust in Manchester.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 30, 2022 Category: Science Authors: Helen Pidd North of England editor Tags: Cancer research Medical research Science NHS Health Society UK news Source Type: news
Developing the joint forward plan
This guidance supports integrated care boards (ICBs) and their partner NHS trusts and foundation trusts to develop their first five-year joint forward plans. (Source: NHS Networks)
Source: NHS Networks - December 29, 2022 Category: UK Health Source Type: news
University hospitals Birmingham: inquiries launched into concerns about bullying and patient safety - Torjesen I.
NHS Birmingham and Solihull Integrated Care Board has announced three major reviews of the culture at University Hospitals Birmingham NHS Foundation Trust and to look into concerns raised by whistleblowers about patient safety and bullying.
A recent BB... (Source: SafetyLit)
Source: SafetyLit - December 19, 2022 Category: International Medicine & Public Health Tags: Jurisprudence, Laws, Legislation, Policies, Rules Source Type: news
‘Inadequate’ trust gets new chief executive
An experienced acute hospital executive has been appointed to lead South Central Ambulance Service Foundation Trust. (Source: HSJ)
Source: HSJ - December 12, 2022 Category: UK Health Source Type: news
Foundation trust and suspended governor urged to avoid legal battle
A judge has urged a foundation trust and the governor it has suspended to settle their differences outside the courts. (Source: HSJ)
Source: HSJ - November 28, 2022 Category: UK Health Source Type: news
‘Witch-hunt’ trust finally gets new CEO
West Suffolk Foundation Trust has appointed a new substantive chief executive just over a year after Steve Dunn stood down from the role following a protracted bullying scandal. (Source: HSJ)
Source: HSJ - November 25, 2022 Category: UK Health Source Type: news
Cancer survival rates could DOUBLE in a decade as research leads to more treatment options
World-leading experts from the Institute of Cancer Research (ICR) and the Royal Marsden NHS Foundation Trust said new research will mean more patients get cured while others live far longer. (Source: the Mail online | Health)
Source: the Mail online | Health - November 22, 2022 Category: Consumer Health News Source Type: news
Scientists reveal new lines of attack to raise cancer survival rate
Targeting non-cancerous cells in tumours could open up new frontiers in fight against the diseaseScientists hope to double the survival rate of people with advanced cancer within a decade by using new lines of attack to fight the disease.Speaking at the launch of a joint five-year research strategy by the Institute of Cancer Research (ICR) and the Royal Marsden NHS foundation trust in London, experts described how targeting non-cancerous cells within tumours could open up new frontiers in the fight against the disease, enabling more people to be cured and others to survive for far longer.Continue reading... (Source: Guardi...
Source: Guardian Unlimited Science - November 22, 2022 Category: Science Authors: Linda Geddes Tags: Cancer research Medical research Science Immunology Biochemistry and molecular biology Health Source Type: news
Heating chemotherapy drugs to 42c can DOUBLE the survival time for patients
Norfolk and Norwich University Hospitals NHS Foundation Trust is the first to offer it to patients after studies showed heating the drugs increased their potency, prolonging life. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2022 Category: Consumer Health News Source Type: news
Ex-civil servant appointed trust CEO
Gloucestershire Health and Care Foundation Trust has appointed a new chief executive. (Source: HSJ)
Source: HSJ - November 14, 2022 Category: UK Health Source Type: news
How a British-made facemask could help 60,000 patients avoid eyeball injections
Following years of clinical trials on the British-made Noctura 400, Ashford and St Peter's Hospitals NHS Foundation Trust in Surrey has put it to use on patients with diabetic retinopathy. (Source: the Mail online | Health)
Source: the Mail online | Health - November 12, 2022 Category: Consumer Health News Source Type: news
Immunocompromised man, 59, is finally cured of Covid after 411 DAYS
Experts at Guy's and St Thomas' NHS Foundation Trust, London, and King's College London described how the unidentified man was unable to get rid of an early variant of the virus. (Source: the Mail online | Health)
Source: the Mail online | Health - November 4, 2022 Category: Consumer Health News Source Type: news
Guidance on good governance and collaboration
NHS England - This guidance, issued under the NHS provider licence, sets clear expectations of collaboration by NHS trusts and foundation trusts and the governance characteristics that trusts must have in place to support this.GuidanceMore detail (Source: The Kings Fund - Health Management Specialist Collection)
Source: The Kings Fund - Health Management Specialist Collection - November 1, 2022 Category: Health Management Authors: The King ' s Fund Library Tags: Integrated care, collaboration and partnership Regulation, governance and accountability Source Type: news
Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO)
Vabysmo achieved its primary endpoint of non-inferiority toaflibercept in RVO in the BALATON and COMINO clinical trialsVabysmo was generally well tolerated, with a safety profile consistent with previous trialsVabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening retinal conditionsDetailed results will be presented at an upcoming medical meeting and submitted to regulatory authorities around the worldBasel, 27 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two global phase I...
Source: Roche Investor Update - October 27, 2022 Category: Pharmaceuticals Source Type: news
Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO)
Vabysmo achieved its primary endpoint of non-inferiority toaflibercept in RVO in the BALATON and COMINO clinical trialsVabysmo was generally well tolerated, with a safety profile consistent with previous trialsVabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening retinal conditionsDetailed results will be presented at an upcoming medical meeting and submitted to regulatory authorities around the worldBasel, 27 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two global phase I...
Source: Roche Media News - October 27, 2022 Category: Pharmaceuticals Source Type: news
